680 related articles for article (PubMed ID: 31836877)
1. Towards personalized treatment for early stage HER2-positive breast cancer.
Goutsouliak K; Veeraraghavan J; Sethunath V; De Angelis C; Osborne CK; Rimawi MF; Schiff R
Nat Rev Clin Oncol; 2020 Apr; 17(4):233-250. PubMed ID: 31836877
[TBL] [Abstract][Full Text] [Related]
2. Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015.
Zardavas D; Fouad TM; Piccart M
Breast; 2015 Nov; 24 Suppl 2():S143-8. PubMed ID: 26255196
[TBL] [Abstract][Full Text] [Related]
3. When to Add Additional Anti-HER2 Therapy to Adjuvant Trastuzumab.
Zimmer AS; Denduluri N
Curr Oncol Rep; 2019 Nov; 21(12):109. PubMed ID: 31781874
[TBL] [Abstract][Full Text] [Related]
4. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
Harbeck N; Gluz O; Christgen M; Kates RE; Braun M; Küemmel S; Schumacher C; Potenberg J; Kraemer S; Kleine-Tebbe A; Augustin D; Aktas B; Forstbauer H; Tio J; von Schumann R; Liedtke C; Grischke EM; Schumacher J; Wuerstlein R; Kreipe HH; Nitz UA
J Clin Oncol; 2017 Sep; 35(26):3046-3054. PubMed ID: 28682681
[TBL] [Abstract][Full Text] [Related]
5. A clinical perspective on escalating or de-escalating adjuvant therapy in HER2+ breast cancer.
Esposito A; Viale G; Criscitiello C; Curigliano G
Expert Rev Clin Pharmacol; 2019 Jan; 12(1):9-16. PubMed ID: 30466330
[No Abstract] [Full Text] [Related]
6. De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial.
Harbeck N; Nitz UA; Christgen M; Kümmel S; Braun M; Schumacher C; Potenberg J; Tio J; Aktas B; Forstbauer H; Grischke EM; Scheffen I; Malter W; von Schumann R; Just M; Zu Eulenburg C; Biehl C; Kolberg-Liedtke C; Deurloo R; de Haas S; Jóźwiak K; Hauptmann M; Kates R; Graeser M; Wuerstlein R; Kreipe HH; Gluz O;
J Clin Oncol; 2023 Aug; 41(22):3796-3804. PubMed ID: 36809046
[TBL] [Abstract][Full Text] [Related]
7. Survival benefit of anti-HER2 therapy after whole-brain radiotherapy in HER2-positive breast cancer patients with brain metastasis.
Zhang Q; Chen J; Yu X; Cai G; Yang Z; Cao L; Hu C; Guo X; Sun J; Chen J
Breast Cancer; 2016 Sep; 23(5):732-9. PubMed ID: 26267412
[TBL] [Abstract][Full Text] [Related]
8. A systematic review of dual targeting in HER2-positive breast cancer.
Kümler I; Tuxen MK; Nielsen DL
Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
[TBL] [Abstract][Full Text] [Related]
9. De-escalating treatment in the adjuvant setting in HER2-positive breast cancer.
Barroso-Sousa R; Exman P; Tolaney SM
Future Oncol; 2018 Apr; 14(10):937-945. PubMed ID: 29589471
[TBL] [Abstract][Full Text] [Related]
10. Optimal treatment of early stage HER2-positive breast cancer.
Pernas S; Barroso-Sousa R; Tolaney SM
Cancer; 2018 Dec; 124(23):4455-4466. PubMed ID: 30291791
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes of neoadjuvant treatment of HER2-positive breast cancer.
Zhang B; Hurvitz S
Clin Adv Hematol Oncol; 2016 Jul; 14(7):520-30. PubMed ID: 27379947
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant trastuzumab: a 10-year overview of its benefit.
Lambertini M; Pondé NF; Solinas C; de Azambuja E
Expert Rev Anticancer Ther; 2017 Jan; 17(1):61-74. PubMed ID: 27883296
[TBL] [Abstract][Full Text] [Related]
13. HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer.
Miller K; Cortes J; Hurvitz SA; Krop IE; Tripathy D; Verma S; Riahi K; Reynolds JG; Wickham TJ; Molnar I; Yardley DA
BMC Cancer; 2016 Jun; 16():352. PubMed ID: 27259714
[TBL] [Abstract][Full Text] [Related]
14. Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?
Constantinidou A; Smith I
Breast; 2011 Oct; 20 Suppl 3():S158-61. PubMed ID: 22015286
[TBL] [Abstract][Full Text] [Related]
15. De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance.
Veeraraghavan J; De Angelis C; Reis-Filho JS; Pascual T; Prat A; Rimawi MF; Osborne CK; Schiff R
Breast; 2017 Aug; 34 Suppl 1(Suppl 1):S19-S26. PubMed ID: 28687441
[TBL] [Abstract][Full Text] [Related]
16. Proteomics as a Guide for Personalized Adjuvant Chemotherapy in Patients with Early Breast Cancer.
Lumachi F; Chiara GB; Foltran L; Basso SM
Cancer Genomics Proteomics; 2015; 12(6):385-90. PubMed ID: 26543084
[TBL] [Abstract][Full Text] [Related]
17. Optimal sequencing of anti-HER2 therapy throughout the continuum of HER2-positive breast cancer: evidence and clinical considerations.
Harbeck N; Wuerstlein R
Drugs; 2013 Oct; 73(15):1665-80. PubMed ID: 24127221
[TBL] [Abstract][Full Text] [Related]
18. Pertuzumab in HER2-positive early breast cancer: current use and perspectives.
Eiger D; Pondé NF; de Azambuja E
Future Oncol; 2019 Jun; 15(16):1823-1843. PubMed ID: 30938542
[TBL] [Abstract][Full Text] [Related]
19. Is trastuzumab as a single agent obsolete in early breast cancer? No.
Bianchini G
Breast; 2019 Feb; 43():142-145. PubMed ID: 30578129
[TBL] [Abstract][Full Text] [Related]
20. Impact of Pertuzumab and Ado-Trastuzumab Emtansine on Cumulative Avoidance of Recurrence Among Women Treated for Locally Advanced, Inflammatory, or Early-Stage Nonmetastatic HER2-Positive Breast Cancer in the United States.
Sussell JA; Press DJ; Hansen SA; Kim E; Du Toit Y; Fung A
Adv Ther; 2023 Sep; 40(9):3857-3874. PubMed ID: 37358705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
